Deutsche Bank Sees 4 Big Pharmaceutical Stocks as Cheap With Solid Dividends
With investors looking for safety and dividends for total return, the big pharmaceutical stocks are just the ticket, and these four are outstanding.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 223
Chimerix Rises Slightly on Revenue Beat
Chimerix reported mixed fourth-quarter financial results before the markets opened on Monday.
Returning Valeant CEO Pearson Needs to Be Fired
Valeant Pharmaceuticals International Inc. (NYSE: VRX) CEO J. Michael Pearson has returned from sick leave. It is a wonder the board has accepted him back, based on what has happened to the pharmaceuticals company this…
How Analysts Changed Views on BioMarin After Earnings
Investors really took to BioMarin Pharmaceuticals stock and there was a favorable jump after the fourth-quarter earnings report.
Top 4 Biopharma Movers of the Past Week
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
The 5 States Where People Get the Least Sleep
Eight hours of sleep. That is the rule most often mentioned as the measure of a good night’s sleep. Some people claim they can get by on less, and for a few, much less.…
Syndax Updates IPO FIling
Syndax Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Why Peregrine Absolutely Tanked
Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer.
Big Pharma Matchup: Valeant vs Gilead
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Why Citi Sees Huge Upside in 4 Top Biotechs Now
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Short Interest Rises Across the Board in Major Biotechs
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Short Sellers Increase Bets in Major Pharma
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Pfizer Sinks Despite Winning FDA Approval
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
PTC Therapeutics Craters on FDA Letter
PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application for Translarna (ataluren).
Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.